GGrantIndex
← Search

Genomics Shared Resource (GSR)

$274,598P30FY2022CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

GENOMICS SHARED RESOURCE (GSR) ABSTRACT Xinmin Li, PhD (ZY), Director, and Ling Dong, PhD, Co-Director, lead the UCLA Jonsson Comprehensive Cancer Center (JCCC) Genomics Shared Resource (GSR). The GSR provides JCCC investigators with state- of-the-art genomics technologies, comprehensive services, specialized expertise, and a wide range of training opportunities, to enable transformative research that is cost-effective and timely. The facility is a high-throughput and fully automated genomics core located in the Center for Health Sciences (CHS) building, near JCCC investigator laboratories. The GSR occupies 2,568 sf. of laboratory and administrative space and is equipped with all major state-of-the-art instruments for genomics analyses including a range of next generation sequencers, microarray platforms, and a single cell 10X Genomics Chromium Controller. Eleven staff members total, including one faculty member, Li, and eight PhD scientists, operate the GSR, providing 76 years of combined genomics experience. The GSR has a broad user base. From 2013 – 2018, the GSR supported 76 unique JCCC investigators in 2,344 research projects from all six JCCC Research Programs. This represents 26% (36,274 JCCC experiments/ 140,087 total experiments) of total Shared Resource usage. Of these 76 JCCC investigators, 22% are peer- review funded. GSR support activities helped to enable 235 publications, of which 151 (64%) were in high-impact (IF ≥10, or field leading) journals. In addition, the GSR supported numerous cancer research projects from cancer investigators at nine non-UCLA cancer centers and served numerous additional external investigators from >150 non-UCLA institutions. JCCC investigators benefited significantly from the large number of external users by enabling a 43% discount in pricing to JCCC member labs during the prior project period while maintaining quick turnaround times from a formal GSR policy that prioritizes JCCC investigators, followed by other UCLA investigators, over external users. The primary goals of the GSR is to provide JCCC investigators with access to state-of-the-art genomic capabilities and genomics training, provide planning assistance for multidisciplinary projects, and enable investigators to develop new applications using the most advanced technologies by continual core upgrades. Through these goals and its service activities, the GSR accelerates the pace of cancer discoveries that support the translational pipeline for implementation in clinical settings.

View original record on NIH RePORTER →